Choosing lung and breast panels by the property each line represents rather than by what grows: why an h1299 cell line whose h1299 cells are a common null background sits beside an h1975 cell line carrying a resistance mutation, an h358 cell line and a pc9 cell line whose pc9 cells are the standard sensitive comparator, where beas2b cells and other bronchial epithelial cells belong as a non-tumour reference, and how a breast panel of an mcf7 cell line, a t47d cell line, an skbr3 cell line whose skbr3 cells are the receptor-amplified member, a 4t1 cell line, an emt6 cell line and an e0771 cell line also catalogued as an eo771 cell line differs from a placental set built on bewo cells, including the hyphenated beas-2b spelling the same bronchial line is catalogued under

Building a panel that supports a conclusion

1. Name the property each line stands for. Driver mutation, tumour suppressor status, receptor expression and resistance mechanism are the properties that usually matter. Write each line's role in the panel down before ordering; if a line has no stated role it is there for convenience rather than for evidence.
2. Include a sensitive and a resistant comparator. Where the work concerns a targeted agent, the panel needs a line that responds and a line that does not, ideally differing by a known mechanism. Without both, a dose response is a description rather than a comparison.
3. Include a non-tumour reference where the claim is selectivity. Immortalised normal epithelial lines exist for exactly this and they are not normal tissue: they are immortalised, culture-adapted and sometimes transformed. They are a useful comparator when described accurately and a misleading one when described as normal cells.
4. Match the species to the question. Mouse lines exist so that a tumour can be grown in an immunocompetent animal of the same strain. That makes them the right choice for immune work and the wrong choice for anything about human genetics, and the strain background has to match the host or the experiment fails for a reason that has nothing to do with biology.
5. Check receptor and marker status against the repository. Receptor expression in long-passaged lines drifts and is reported inconsistently in the literature. Take the repository's characterisation as the reference and confirm the markers your conclusion depends on in your own hands rather than citing a paper from twenty years ago.

Immune-competent models and their constraints

A tumour line that grows in a mouse with an intact immune system is the only way to study an immune mechanism in vivo, and it constrains everything else: the line has to match the host strain, the genetics are mouse rather than human, and the tumour grows far faster than a human tumour does.

Where the same question is asked in human lines, it is asked in an immunodeficient host or in a reconstituted system, each with its own limitations. Stating which compromise you have accepted is part of the result rather than a caveat.

Culture conditions change the phenotype

Receptor expression, differentiation state and drug sensitivity all shift with serum batch, confluence, passage number and medium. Two laboratories running the same line under different conditions can legitimately disagree about its phenotype.

The practical answers are a working bank at a recorded passage, a fixed medium and serum arrangement for the duration of a study, and the conditions recorded in the methods. None of these is expensive and together they remove most of the irreproducibility attributed to the lines themselves.

Non-tumour references, described honestly

Immortalised epithelial lines used as a normal comparator have been altered to grow indefinitely, which is itself a change in the biology being compared. They are valuable and they are not primary cells, and the distinction belongs in the description.

Where the claim is selectivity against normal tissue, primary cells from the relevant tissue are the stronger comparator, with their own constraints on availability and lifespan. Choosing between them is a judgement about what the conclusion has to survive.

One line, two spellings, one accession

Immortalised bronchial epithelial cells are catalogued with and without a hyphen, and a search on one spelling misses stock listed under the other. The accession is the identifier that resolves it, and it is what belongs in a methods section.

The line is immortalised rather than primary, which is the more important point: it is a useful non-tumour comparator and it is not normal airway epithelium, and describing it accurately is what keeps a selectivity claim honest.

Common questions

Why include a resistant line?

Because a dose response in sensitive lines alone describes the agent rather than testing a mechanism. A resistant comparator differing by a known mechanism turns the experiment into a comparison.

Are immortalised epithelial lines normal cells?

No. They have been altered to grow indefinitely, which changes the biology being compared. They are useful references when described accurately; where selectivity against normal tissue is the claim, primary cells are the stronger comparator.

Can I use a mouse tumour line for human genetics?

No. Those lines exist so a tumour can grow in an immunocompetent host of the same strain, which is right for immune work and wrong for human genetics. The strain has to match the host or the experiment fails for non-biological reasons.

Is an immortalised bronchial line normal airway epithelium?

No. It is immortalised and culture-adapted, which makes it a useful non-tumour comparator rather than normal tissue. Where selectivity against normal airway is the claim, primary cells are the stronger comparator.

Browse by service class

• Compare Gene synthesis on advertised prices